Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors

Lee, Su; Lee, Seon; Lee, Weon; Yoo, Jin; Sun, Jong-Mu; Lee, Jeeyun; Park, Se; Park, Joon; Ahn, Myung-Ju; Lim, Ho; Kang, Won; Park, Young
December 2017
Investigational New Drugs;Dec2017, Vol. 35 Issue 6, p782
Academic Journal
Background Tanibirumab is a fully human monoclonal antibody to vascular endothelial growth factor receptor 2 (VEGFR-2). We conducted a first-in-human phase I study of tanibirumab in patients with solid tumors refractory to standard chemotherapy. Primary endpoints were evaluating safety, pharmacokinetics (PKs), estimating maximum-tolerated dose (MTD) and recommended phase II dose (RP2D). Methods We designed our study to escalate tanibirumab at 9 different dose levels with a 3 + 3 method and tanibirumab (1-28 mg/kg) was administered intravenously on D1, 8, 15 in 28-day courses. Dose limiting toxicities (DLTs) were only assessed during the first cycle of treatment and response evaluation was performed every 2 cycles. The effects of tanibirumab on several angiogenic factors were analyzed. Results From October 2011 to September 2013, a total of 26 patients with refractory solid tumors were enrolled. The median age was 58 years (range, 27-75) and 20 patients were male. The most common tumor type was colorectal cancer ( N = 19) and seven patients had a history of previous bevacizumab treatment. As hemangioma continued to occur, the final dose level, 28 mg/kg, was not performed. DLTs were not found, and the MTD was confirmed to be 24 mg/kg. Hemangioma was observed in 16 patients (61.5%), but all were grade 1-2 and disappeared after discontinuation of the study drug. Among the 18 patients in the efficacy set, no objective response was observed, but 11 patients showed stable disease. PKs were characterized by dose-dependent linear exposure and the mean trough concentrations exceeded biologically relevant target levels at 12 mg/kg and above. Serum VEGF, soluble VEGFR-2, and PlGF increased at the 4 mg/kg dose level and above. Conclusions Treatment with tanibirumab showed a tolerable toxicity profile and modest clinical efficacy in patients with refractory solid tumors. A phase II trial of tanibirumab is ongoing now.


Related Articles

  • Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer. Reddy, S.; Kopetz, S.; Morris, J.; Parikh, N.; Qiao, W.; Overman, M.; Fogelman, D.; Shureiqi, I.; Jacobs, C.; Malik, Z.; Jimenez, C.; Wolff, R.; Abbruzzese, J.; Gallick, G.; Eng, C. // Investigational New Drugs;Aug2015, Vol. 33 Issue 4, p977 

    Background Src has a critical role in tumor cell migration and invasion. Increased Src activity has been shown to correlate with disease progression and poor prognosis, suggesting Src could serve as a therapeutic target for kinase inhibition. Saracatinib (AZD0530) is a novel selective oral Src...

  • Development of Monoclonal Antibodies in China: Overview and Prospects. Zhang, Mao-Yu; Lu, Jin-Jian; Wang, Liang; Gao, Zi-Chao; Hu, Hao; Ung, Carolina Oi Lam; Wang, Yi-Tao // BioMed Research International;2/25/2015, Vol. 2015, p1 

    Monoclonal antibodies (mAbs) have become increasingly important as human therapeutic agents. Yet, current research concentrates on technology itself and pays attention to developed countries. This paper aims to provide a comprehensive review of mAbs development in China through systematic...

  • A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer. Bennouna, Jaafar; Deslandres, Marion; Senellart, Helene; Labareyre, Cecile; Ruiz-Soto, Rodrigo; Wixon, Claire; Botbyl, Jeff; Suttle, A.; Delord, Jean-Pierre // Investigational New Drugs;Feb2015, Vol. 33 Issue 1, p138 

    Background Pazopanib is a multi-targeted tyrosine kinase inhibitor shown to be clinically active in the treatment of various cancer types. This study aimed to evaluate the maximum tolerated regimen (MTR), safety, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab in...

  • Molecular Events in Primary and Metastatic Colorectal Carcinoma: A Review. Kanthan, Rani; Senger, Jenna-Lynn; Chandra Kanthan, Selliah // Pathology Research International;2012, p1 

    Colorectal cancer (CRC) is a heterogeneous disease, developing through a multipathway sequence of events guided by clonal selections. Pathways included in the development of CRC may be broadly categorized into (a) genomic instability, including chromosomal instability (CIN), microsatellite...

  • Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13). Harter, Philipp; Sehouli, Jalid; Kimmig, Rainer; Rau, Jörn; Hilpert, Felix; Kurzeder, Christian; Elser, Gabriele; Bois, Andreas // Investigational New Drugs;Dec2013, Vol. 31 Issue 6, p1499 

    Background PLD is a standard treatment in patients with recurrent platinum-resistant or refractory ovarian cancer. Vandetanib is an oral once daily administered inhibitor of VEGFR-, EGFR- and RET-signaling with activity in combination with chemotherapy in some solid tumours. We aimed to...

  • The Molecular Basis of Class Side Effects Due to Treatment with Inhibitors of the VEGF/VEGFR Pathway. Roodhart, Jeanine M.; Langenberg, Marlies H.; Witteveen, Els; Voest, Emile E. // Current Clinical Pharmacology;May2008, Vol. 3 Issue 2, p132 

    Vascular Endothelial Growth Factor (VEGF) is considered to be one of the most important regulators of angiogenesis and a new key target in anti-cancer treatment. Various clinical trials have validated the clinical importance of anti-VEGF or anti-VEGF receptor (VEGFR) therapy. Currently the...

  • Bevacizumab in colorectal cancer: profile report. Adis International Limited // Drugs & Therapy Perspectives;May2005, Vol. 21 Issue 5, p5 

    Focuses on the effectiveness of bevacizumab, a recombinant humanised monoclonal antibody directed against vascular endothelial growth factor, in treating colorectal cancer. Dosage of bevacizumab administered to patients; Adverse events of bevacizumab; Effect of the drug on the gastrointestinal...

  • A phase I, dose-escalation study of TB-403, a monoclonal antibody directed against PlGF, in patients with advanced solid tumours. Lassen, U; Nielsen, D L; Sørensen, M; Winstedt, L; Niskanen, T; Stenberg, Y; Pakola, S; Stassen, J-M; Glazer, S // British Journal of Cancer;2/14/2012, Vol. 106 Issue 4, p678 

    Background:TB-403 (RO 5323441), a humanised monoclonal antibody, is a novel antiangiogenesis agent directed against placental growth factor. The safety, pharmacokinetics (PK), and antitumour activity of TB-403 were assessed in a phase I, dose-escalation study in patients with advanced solid...

  • A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors. Patnaik, Amita; LoRusso, Patricia; Messersmith, Wells; Papadopoulos, Kyriakos; Gore, Lia; Beeram, Muralidhar; Ramakrishnan, Vanitha; Kim, Amy; Beyer, Joseph; Mason Shih, L.; Darbonne, Walter; Xin, Yan; Yu, Ron; Xiang, Hong; Brachmann, Rainer; Weekes, Colin // Cancer Chemotherapy & Pharmacology;May2014, Vol. 73 Issue 5, p951 

    Purpose: MNRP1685A is a human monoclonal antibody that blocks binding of vascular endothelial growth factor (VEGF), VEGF-B, and placental growth factor 2 to neuropilin-1 resulting in vessel immaturity and VEGF dependency. The safety of combining MNRP1685A with bevacizumab, with or without...

  • Ranibizumab.  // Reactions Weekly;Apr2015, Vol. 1546 Issue 1, p177 

    The article presents case reports of three patients who developed endophthalmitis during treatment with ranibizumab for neovascular age-related macular degeneration. It is noted that prior to intravitreal injection (IVI), a periocular scrub using povidone/iodine (PVI) was performed and PVI drops...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics